Biocept Announces Pricing of $10.0 Million Underwritten Public Offering
6 minutes ago | San Diego Biotechnology | 2 articles
SAN DIEGO, Dec. 9, 2019 /PRNewswire/ - Biocept, Inc. , a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering...
Read more ...
ASH: Roche bispecific delivers for hard-to-treat lymphoma patients failed by CAR-Ts
16 minutes ago | Fierce Biotech
Roche has rolled out new data showing mosunetuzumab can trigger complete responses in a tough group-lymphoma patients failed by CAR-Ts and other drugs. The phase 1/2b linked...
Read more ...
Sanofi inks $2.5B Synthorx takeover to gain IL-2 cancer drug
16 minutes ago | Fierce Biotech | 2 articles
Sanofi has struck a deal to buy Synthorx for $2.5 billion. The takeover, the first of Paul Hudson's time as CEO, will give Sanofi control of an IL-2 drug it thinks can become a...
Read more ...
ASH: Amgen's BiTE stalls multiple myeloma relapse in mice in combo with BMS' Revlimid
16 minutes ago | Fierce Biotech
Amgen is developing two bispecific T-cell engagers for multiple myeloma, one of which is designed with a longer half-life that could lessen the infusion time required for...
Read more ...
AstraZeneca Taps Gatehouse Bio to Identify Potential Drug Targets
58 minutes ago | Xconomy
After joining AstraZeneca's Boston Bio Hub incubator last year, Gatehouse Bio is now teaming up with the pharma company to identify potential drug targets in respiratory and...
Read more ...
Alert: Johnson Fistel Investigates Proposed Sale of ArQule, Inc.; Is $20 a Fair Price?
1 hour ago | San Diego Biotechnology | 2 articles
SAN DIEGO, Dec. 9, 2019 /PRNewswire/ - Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of ArQule, Inc. breached...
Read more ...
New Sanofi CEO Hudson adds next-gen cancer drug tech to the R&D quest, buying Synthorx for $2.5B
2 hours ago | San Diego Biotechnology | 2 articles
When Paul Hudson lays out his R&D vision for Sanofi tomorrow, he will have a new slate of interleukin therapies and a synthetic biology platform to boast about.
The French...
Read more ...
Process Engineer I - Genentech - Oceanside, CA
4 hours ago | San Diego Biotechnology
Focus will be on one or more areas such as design, implementation and/or start-up of new and/or existing facilities with respect to process and/or clean utility...From...
Read more ...
AveXis Inc.: Senior Scientific Training Specialist - cGMP Gene Therapy
4 hours ago | San Diego Biotechnology
AveXis Inc.:
OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated by rare neurological gene
San Diego...
Read more ...
The majority of A-to-I RNA editing is not required for mammalian homeostasis
5 hours ago | Springer
Abstract
Background
Adenosine-to-inosine RNA editing, mediated by ADAR1 and ADAR2, occurs at tens of thousands to millions of sites across mammalian transcriptomes. A-to-I...
Read more ...
Register you to post on BioTech Mag
Free Registration
World Biotechnology Congress 2019
Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...
World Biotechnology Congress 2019
Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...
2nd International Conference on Tissue Science and Regenerative Medicine
This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...
AstraZeneca Taps Gatehouse Bio to Identify Potential Drug Targets
After joining AstraZeneca's Boston Bio Hub incubator last year, Gatehouse Bio is now teaming up with the pharma company to identify potential drug targets in respiratory and... Read more ...
IAmScience Mannie Liscum
For Mannie Liscum, thinking is a privilege, and his job gives him the chance to be fascinated by human's capacity to conceptualize and learn new things. “It's my goal to use as... Read more ...
Alert: Johnson Fistel Investigates Proposed Sale of ArQule, Inc.; Is $20 a...
SAN DIEGO, Dec. 9, 2019 /PRNewswire/ - Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of ArQule, Inc. breached... Read more ...
New Sanofi CEO Hudson adds next-gen cancer drug tech to the R&D quest...
When Paul Hudson lays out his R&D vision for Sanofi tomorrow, he will have a new slate of interleukin therapies and a synthetic biology platform to boast about. The French... Read more ...
AveXis Inc.: Senior Scientific Training Specialist - cGMP Gene Therapy
AveXis Inc.: OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated by rare neurological gene San Diego... Read more ...
Process Engineer I - Genentech - Oceanside, CA
Focus will be on one or more areas such as design, implementation and/or start-up of new and/or existing facilities with respect to process and/or clean utility...From... Read more ...
Pineoblastoma segregates into molecular sub-groups with distinct...
Abstract Pineoblastomas are rare, aggressive pediatric brain tumors of the pineal gland with modest overall survival despite intensive therapy. We sought to define the clinical... Read more ...
The majority of A-to-I RNA editing is not required for mammalian homeostasis
Abstract Background Adenosine-to-inosine RNA editing, mediated by ADAR1 and ADAR2, occurs at tens of thousands to millions of sites across mammalian transcriptomes. A-to-I... Read more ...
CRISPR System: A High-throughput Toolbox for Research and Treatment of...
Abstract In recent years, the innovation of gene-editing tools such as the CRISPR/Cas9 system improves the translational gap of treatments mediated by gene therapy. The... Read more ...
Exploration of cryptic organic photosensitive compound as Zincphyrin IV in...
Abstract Zincphyrin IV is a potential organic photosensitizer which is of significant interest for applications in biomedicine, materials science, agriculture , and chemistry... Read more ...